. 2016 Feb 24;8(10):16190–16201. doi: 10.18632/oncotarget.7668

Table 4. Association of clinical and tumor characteristics, XPC c.2815A>C, XPD c.934G>A, XPD c.2251A>C, XPF c.2505T>C and ERCC1 c.354C>T single nucleotide polymorphisms genotypes with survival of head and neck squamous cell carcinoma patients treated with chemoradiotherapy in univariate Cox analysis.

Variables	Progression-free survival			Overall survival
Variables	N with event/N total	P value	HR (95% CI)	N with event/N total	P value	HR (95% CI)
Age (years)
≤ 56	32/46	0.40	1.24 (0.74-2.06)	29/46	0.79	1.08 (0.57-2.05)
> 56	28/44	0.40	1.24 (0.74-2.06)	30/44	0.79	1.08 (0.57-2.05)
Gender
Male	54/83	0.22	1.68 (0.72-3.93)	55/83	0.86	1.10 (0.34-3.60)
Female	6/7	0.22	1.68 (0.72-3.93)	4/7	0.86	1.10 (0.34-3.60)
Tobacco consumption
Smokers	58/88	0.12	3.05 (0.73-12.67)	58/88	0.72	1.43 (0.19-10.44)
Non-smokers	2/2	0.12	3.05 (0.73-12.67)	1/2	0.72	1.43 (0.19-10.44)
Alcohol consumption
Drinkers	57/83	0.30	1.83 (0.57-5.89)	57/83	0.21	3.52 (0.48-25.71)
Abstainers	3/7	0.30	1.83 (0.57-5.89)	2/7	0.21	3.52 (0.48-25.71)
Tumor location
Oral cavity/oropharynx	36/51	0.47	1.20 (0.71-2.03)	36/51	0.24	1.48 (0.76-2.91)
Hypopharynx/larynx	24/39	0.47	1.20 (0.71-2.03)	23/39	0.24	1.48 (0.76-2.91)
Histological grade
Well/moderately	39/60	0.28	1.48 (0.71-3.08)	38/60	0.44	1.32 (0.64-2.75)
Poorly/undifferentiated	9/13	0.28	1.48 (0.71-3.08)	9/13	0.44	1.32 (0.64-2.75)
Tumor stage
I + II	1/6	0.06	6.64 (0.91-48.05)*	1/6	0.05	7.08 (0.97-51.28)^*
III + IV	59/84	0.06	6.64 (0.91-48.05)*	58/84	0.05	7.08 (0.97-51.28)^*
XPC c.2815A>C
AA+AC	51/77	0.90	1.04 (0.51-2.12)	51/77	0.47	1.31 (0.62-2.77)
CC	9/13	0.90	1.04 (0.51-2.12)	8/13	0.47	1.31 (0.62-2.77)
AA	21/32	0.82	1.06 (0.62-1.80)	22/32	0.58	1.15 (0.68-1.96)
AC+CC	39/58	0.82	1.06 (0.62-1.80)	37/58	0.58	1.15 (0.68-1.96)
XPD c.934G>A
GG+GA	51/80	0.02	2.33 (1.13-4.77)^***	50/80	0.02	2.24 (1.09-4.61)^****
AA	9/10	0.02	2.33 (1.13-4.77)^***	9/10	0.02	2.24 (1.09-4.61)^****
GG	30 / 48	0.38	1.25 (0.75-2.07)	31/48	0.75	1.08 (0.65-1.81)
GA+AA	30/42	0.38	1.25 (0.75-2.07)	28/42	0.75	1.08 (0.65-1.81)
XPD c.2251A>C
AA+AC	56/82	0.46	1.45 (0.52-4.02)	55/82	0.51	1.40 (0.50-3.88)
CC	4/8	0.46	1.45 (0.52-4.02)	4/8	0.51	1.40 (0.50-3.88)
AA	26/44	0.19	1.40 (0.84-2.33)	28/44	0.71	1.10 (0.66-1.83)
AC+CC	34/46	0.19	1.40 (0.84-2.33)	31/46	0.71	1.10 (0.66-1.83)
XPF c.2505T>C
TT+TC	56/83	0.75	1.17 (0.42-3.24)	55/83	0.85	1.10 (0.39-3.04)
CC	4/7	0.75	1.17 (0.42-3.24)	4/7	0.85	1.10 (0.39-3.04)
TT	26/41	0.60	1.14 (0.68-1.90)	25/41	0.40	1.24 (0.74-2.10)
TC+CC	34/49	0.60	1.14 (0.68-1.90)	34/49	0.40	1.24 (0.74-2.10)
ERCC1 c.354C>T
CC+CT	52/74	0.11	1.92 (0.91-4.06)	51/74	0.15	1.72 (0.81-3.65)
TT	8/16	0.11	1.92 (0.91-4.06)	8/16	0.15	1.72 (0.81-3.65)
CC	19/25	0.35	1.29 (0.74-2.22)	18/25	0.64	1.13 (0.65-1.98)
CT+TT	41/65	0.35	1.29 (0.74-2.22)	41/65	0.64	1.13 (0.65-1.98)

(N) number of patients; (HR) hazard ratio; (CI) confidence interval. Significant differences between groups are presented in bold letters. In multivariate Cox analysis (adjusted by tumor stage and XPD c.934G>A polymorphism): *P= 0.07, HR: 6.15, 95% CI: 0.84-44.68; ^*P= 0.06, HR: 6.59, 95% CI: 0.90-47.90; ^***P= 0.03, HR: 2.13, 95% CI: 1.04-4.38; ^****P= 0.05, HR: 2.04, 95% CI: 1.00-4.20.